Composition:
1 tab Ginkgo biloba leaf extract (EGb 761®) 40 mg, incl. flavonol glycosides 22-26.4% ginkgolides-bilobalides 5.4-6.6% Excipients: lactose monohydrate - 82.5 mg, microcrystalline cellulose - 50 mg, corn starch - 37 mg, colloidal silicon dioxide - 28 mg, talc - 11.25 mg, magnesium stearate - 1.25 mg .
Shell composition: hypromellose (E464) - 6 mg, macrogol 400 - 1.5 mg, macrogol 6000 - 1.5 mg, titanium dioxide (E171) - 1 mg, iron oxide red (E172) - 0.7 mg.
Pharmacodynamics:
Angioprotective agent of plant origin. A standardized and titrated herbal preparation, the effect of which is due to the effect on the metabolic processes in cells, the rheological properties of blood, as well as on vasomotor reactions of blood vessels. The drug improves the supply of oxygen and glucose to the brain. It normalizes the tone of arteries and veins, improves microcirculation. Helps to improve blood flow, prevents the aggregation of red blood cells. It has an inhibitory effect on platelet activation factor. Improves metabolic processes, has an antihypoxic effect on tissues. Prevents the formation of free radicals and lipid peroxidation of cell membranes.
It affects the release, reuptake and catabolism of neurotransmitters (norepinephrine, acetylcholine, dopamine, serotonin) and their ability to bind to membrane receptors.
Pharmacokinetics:
Ginkgolides A and B and bilobalides have an oral bioavailability of 80% to 90%. Cmax is achieved after 1-2 hours; T1 / 2 is from 4 hours (Ginkgolid A and bilobalide) to 10 hours (Ginkgolid B). The main route of excretion is the kidneys. Side effects Allergic reactions: redness, skin rash, swelling, itching, urticaria.
From the coagulation system of the blood: a decrease in blood coagulability and the possibility of bleeding (with prolonged use). Dermatological reactions: eczema. From the side of the central nervous system: headache, dizziness, tinnitus.
From the digestive system: nausea, vomiting, abdominal pain, dyspepsia, diarrhea. In case of adverse reactions, the patient should stop taking the drug and consult a doctor.
Special conditions:
Improvement appears 1 month after the start of treatment. Since Tanakan® in the form of tablets contains lactose, it should not be prescribed to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or with lactase deficiency. 450 mg of ethyl alcohol (57% v / v) is contained in a single dose of the oral solution, and a maximum daily dose of 1.35 g of ethyl alcohol.
Impact on the ability to drive vehicles and control mechanisms During the period of taking the drug, it is not recommended to perform potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions (including driving, working with moving mechanisms), because the drug may cause dizziness and the solution contains ethyl alcohol.
Indications:
- cognitive and sensorineural deficit of various origins (with the exception of Alzheimer's disease and dementia of various etiologies);
- intermittent claudication in chronic obliterating arteriopathies of the lower extremities;
- visual impairment of vascular origin, a decrease in its severity; - hearing impairment, tinnitus, dizziness and coordination disorders mainly of vascular origin;
- Raynaud’s disease and syndrome.
Contraindications:
Age to 18. years.
Hypersensitivity; to any of the components of the drug, erosive gastritis in the stage of exacerbation, gastric ulcer and duodenal ulcer:
guts - in stage * exacerbations, acute cerebrovascular accident, acute myocardial infarction ,. congenital "galactosemia, lactase deficiency, - lactose intolerance, 'glucose-galactose malabsorption, decreased blood coagulability / APPLICATION DURING PREGNANCY AND BREAST-FEEDING Due to the lack of clinical data on the use of the drug during pregnancy and breastfeeding, the purpose of this drug contraindicated.
Drug Interactions:
In clinical studies with EGb 761, both inhibition and induction of cytochrome P450 isoenzymes were detected. With the combined use of EGb 761 with midazolam, the level of the latter changed presumably due to exposure to CYP3A4. Therefore, caution must be exercised when taking EGb 761 and drugs metabolized with the CYP3A4 isoenzyme. With the simultaneous use of Tanakan in the form of an oral solution with antibiotics, a group of cephalosporins (cefamandol, cefoperazone, latamoxef), gentamicin, chloramphenicol, disulfiram, thiazide diuretics, anticonvulsants, oral hypoglycemic drugs (chlorpropamide, glibenfide, possibly glibenfide lactic acidosis)), antifungal drugs (griseofulvin), 5-nitroimidazole derivatives (metronidazole, ornidazole, secnidazole, tinidazole), cytostatics (pro carbazine), tricyclic antidepressants, tranquilizers may occur
Dosage:
Assign 40 mg (1 tablet) 3 times with meals. Take inside. The tablet should be washed down with half a glass of water, the solution for oral administration should be dissolved in half a glass of water. The minimum course of treatment is 3-6 months.
oral solution:
Use a dosing pipette: 1 dose = 1 ml of oral solution = 40 mg of Ginkgo biloba leaf extract. 3 doses (3 ml) per day, distributed throughout the day. Doses should be diluted in 1/2 glass of water and taken with meals.
